NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons (COVID ARC 19)

This study is NOT currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Institutes of Health Clinical Center (CC)

Recruitment Detail

Type: Completed Study; data analyses ongoing
Gender: Male & Female
Min Age: 18 Years
Max Age: 80 Years

Referral Letter Required


Population Exclusion(s)

Pregnant Women;


Immunological Function;
Neurologic Function;
Cardiac Function;
Pulmonary Function;
Natural History

Recruitment Keyword(s)



Acute and long term effects of COVID-19 on systemic inflammation;
Acute and long term effects of COVID-19 on lung function;
Acute and long term effects of COVID-19 on cardiac function;
Acute and long term effects of COVID-19 on kidney function;
Acute and long term effects of COVID-19 on brain function

Investigational Drug(s)


Investigational Device(s)




Supporting Site

NIH Clinical Center


COVID-19 virus infection differs among people. Some people have no or mild symptoms. For others, COVID-19 is life threatening and causes damage to the body s organs. Researchers want to better understand the virus to learn how to kill it.


To understand how the COVID-19 virus causes wide differences in how sick one can become from the infection.


People ages 18-80 with COVID-19 infection


Participants will be screened with a review of their medical records.

Participants who enter the study at the beginning of their COVID-19 infection will stay in the hospital until they are healthy enough to go home. Those who enter after they have recovered may need to stay in the hospital 1-2 nights to perform the study tests.

Participants will have MRI and CT scans of the brain, heart, and lungs. They will lie in a machine that takes pictures of the body. For the MRI, soft padding or a coil will be placed around their head and chest. They may receive a dye injected into a vein.

Participants will have an ultrasound of the kidneys and heart.

Participants will provide blood and urine samples. They will provide nasal swabs.

Participants will have a bronchoscopy. A thin tube will be placed through the nose or mouth into the airway. Saltwater will be squirted into the lungs and removed by suction.

Participants may provide a spinal fluid sample. A needle injected into the spinal canal will obtain fluid.

Participants will have lung and heart function tests.

At various points after recovery, participants will repeat many of these tests.

--Back to Top--



In order to be eligible to participate in this study, an individual must meet all of the following criteria:

Subjects within 1-28 days of documented COVID-19 infection for acute care:

-Stated willingness to comply with all study procedures and availability for the duration of the study

-Male or female, aged 18 to 80 years

--Only a minority of children and adolescents have been described as developing serious illness with COVID-19 infection. As such, this is not an age group at significant risk from complications due to this infection. Adults older than 80 years of age represent a group with the greatest risk of mortality from COVID-19 infection. The presence of significant co-morbidities requiring care that cannot be

provided at the CC would present a disadvantage to them to have their acute care provided for in the CC.

-Documentation of positive SARSCoV-19 test by nucleic acid detection (COVID-19 infection , RT-PCR)

-Ability of subject to understand and the willingness to sign a written informed consent document.

Subjects during recovery phase of the acute illness (day 28 +/- 7 days to 12 weeks) and convalescent phase (Week 13 up to 12 months), Year 2 convalescent phase (13 24 months), Year 3 convalescent phase (25 36 months) after recovery if care has been received at a facility outside of NIH:

-Stated willingness to comply with all study procedures and availability for the duration of the study.

-Male or female, aged 18 to 80 years.

-Study participants will be invited to continue their participation in the study in years 2 and 3 based on the results of their tests from the first year and their willingness to continue for the two additional years. If test results of imaging, blood, pulmonary function and or bronchoscopy have returned to normal at the end of one year, the need for further cardiopulmonary testing will be assessed for each patient. Anyone who is invited to continue in the 2nd and 3rd years may discontinue their participation at any time.


An individual who meets any of the following criteria will be excluded from participation in this study:

- Pregnancy or lactation Study participants who are enrolled in the study and become pregnant during the enrollment period will be discontinued from further study participation. Exposure to radiation or radiographic contrast agents for research purposes .only would not be warranted for a pregnant woman and her fetus.

- Serious mental illness (e.g. schizophrenia, manic depression) that would limit the ability of the participant to participate willingly into the study.

-- The conduct of the study requires participation in studies that may be unduly stressful (e.g. MRI, bronchoscopy).

- Severe claustrophobia that would prohibit the conduct of imaging by MRI even if sedation is provided.

- Cardiac pacemaker or implantable defibrillator unless it is safe for MRI

- Cerebral aneurysm clip unless it is safe for MRI

- Brain stimulator (e.g. TENS-Unit) unless it is safe for MRI

- Any type of ear implant unless it is safe for MRI

- Foreign body in the eye (e.g. metal shavings)

- Metal shrapnel or bullet

- Any implanted device (e.g. insulin pump, drug infusion device

- Patients requiring mechanical ventilation at an outside hospital prior to transfer. Transporting these patients adds risk to their care.

--Back to Top--


Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Li Y, Hu B. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020 Apr 10. doi: 10.1001/jamaneurol.2020.1127. [Epub ahead of print]

Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, Brown TS, Der Nigoghossian C, Zidar DA, Haythe J, Brodie D, Beckman JA, Kirtane AJ, Stone GW, Krumholz HM, Parikh SA. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. J Am Coll Cardiol. 2020 May 12;75(18):2352-2371. doi: 10.1016/j.jacc.2020.03.031. Epub 2020 Mar 19.

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Anthony F. Suffredini, M.D.
National Institutes of Health Clinical Center (CC)
(301) 496-9320

Doris Z. Swaim, R.N.
National Institutes of Health Clinical Center (CC)
National Institutes of Health
Building 10
Room 2C145
10 Center Drive
Bethesda, Maryland 20892
(301) 827-9716

Natural History COVID Study (COVID ARC 19)

Not Listed

Clinical Trials Number:


--Back to Top--